dc.contributor.author | Halef Okan Doğan | |
dc.contributor.author | Cevdet Zungun | |
dc.contributor.author | Fatma Meriç Yılmaz | |
dc.contributor.author | Damla Kayalp | |
dc.contributor.author | Gökmen Zararsız | |
dc.date.accessioned | 23.07.201910:49:13 | |
dc.date.accessioned | 2019-07-23T16:18:13Z | |
dc.date.available | 23.07.201910:49:13 | |
dc.date.available | 2019-07-23T16:18:13Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 2149-2247 | |
dc.identifier.uri | http://www.trdizin.gov.tr/publication/paper/detail/TWpBMU1ESXpNdz09 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/857 | |
dc.description.abstract | Objective: Factor V (FV) (1691 G-A) and methylenetetrahydrofolate reductase (MTHFR) (677 C-T) mutations have been identified as potential risk factors for cardiovascular disease. In this study, we determined vitamin B12, folate, and total homocysteine t(Hcy) concentrations in heterozygote MTHFR (677 C-T) and FV (1691 G-A) mutation-carrying individuals.Materials and Methods: The study included a total of 74 individuals with MTHFR (677 C-T) or FV (1691 G-A) mutations and 70 controls. All subjects had the history of thromboembolic disease. t(Hcy), folate, and vitamin B12 concentrations were compared between the groups.Results: A significant difference was found in vitamin B12 and folate concentrations between patients and controls in the MTHFR (677 C-T) group (p=0.041, p=0.049, respectively). Further, t(Hcy) concentrations were found to be higher in patients than in controls in the FV (1691 G-A) mutation-carrying group (p=0.002). No significant difference was found between the groups in relation with gender in both mutations.Conclusion: t(Hcy) concentrations should be assessed to decrease the risk of future venous thromboembolism in the presence of heterozygote FV (1691 G-A) mutation. | en_US |
dc.description.abstract | Objective: Factor V (FV) (1691 G-A) and methylenetetrahydrofolate reductase (MTHFR) (677 C-T) mutations have been identified as potential risk factors for cardiovascular disease. In this study, we determined vitamin B12, folate, and total homocysteine t(Hcy) concentrations in heterozygote MTHFR (677 C-T) and FV (1691 G-A) mutation-carrying individuals.Materials and Methods: The study included a total of 74 individuals with MTHFR (677 C-T) or FV (1691 G-A) mutations and 70 controls. All subjects had the history of thromboembolic disease. t(Hcy), folate, and vitamin B12 concentrations were compared between the groups.Results: A significant difference was found in vitamin B12 and folate concentrations between patients and controls in the MTHFR (677 C-T) group (p=0.041, p=0.049, respectively). Further, t(Hcy) concentrations were found to be higher in patients than in controls in the FV (1691 G-A) mutation-carrying group (p=0.002). No significant difference was found between the groups in relation with gender in both mutations.Conclusion: t(Hcy) concentrations should be assessed to decrease the risk of future venous thromboembolism in the presence of heterozygote FV (1691 G-A) mutation. | en_US |
dc.language.iso | eng | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Genel ve Dahili Tıp | en_US |
dc.title | Homocysteine Concentrations in Heterozygote MTHFR (677C-T) and Factor V (1691 G-A) Mutation-carrying Individuals with the History of Thromboembolic Disease | en_US |
dc.type | article | en_US |
dc.relation.journal | Erciyes Medical Journal | en_US |
dc.contributor.department | Sivas Cumhuriyet Üniversitesi | en_US |
dc.identifier.volume | 38 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.endpage | 24 | en_US |
dc.identifier.startpage | 20 | en_US |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US] |